HTG Molecular Diagnostics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HTG Molecular Diagnostics stock.
View analyst ratings for HTG Molecular Diagnostics or view top-rated stocks.

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

HTG Molecular Diagnostics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 171,800 shares, a decline of 35.4% from the August 15th total of 265,800 shares. Based on an average daily volume of 85,400 shares, the short-interest ratio is presently 2.0 days.
View HTG Molecular Diagnostics' Short Interest.

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for HTG Molecular Diagnostics.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) posted its earnings results on Thursday, May, 13th. The medical research company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.15. The medical research company earned $1.44 million during the quarter, compared to analysts' expectations of $1.40 million. HTG Molecular Diagnostics had a negative net margin of 218.26% and a negative trailing twelve-month return on equity of 112.47%.
View HTG Molecular Diagnostics' earnings history.

2 analysts have issued 1-year target prices for HTG Molecular Diagnostics' shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $9.50 in the next year. This suggests a possible upside of 58.6% from the stock's current price.
View analysts' price targets for HTG Molecular Diagnostics or view top-rated stocks among Wall Street analysts.

11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to HTG Molecular Diagnostics include Precipio (PRPO), Astrotech (ASTC), SeqLL (SQL), Scientific Industries (SCND), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH), PositiveID (PSID), Arrayit (ARYC), DiaSys (DYXC) and Orthometrix (OMRX).
View all of HTGM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (8.42%), Cowen Prime Advisors LLC (7.85%), Samjo Capital LLC (7.35%), Vanguard Group Inc. (3.35%), Blue Water Life Science Advisors LLC (1.99%) and Worth Venture Partners LLC (1.97%).
View institutional ownership trends for HTG Molecular Diagnostics.

HTGM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, and Blue Water Life Science Advisors LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or view top insider-selling stocks.

HTGM stock was acquired by a variety of institutional investors in the last quarter, including Cowen Prime Advisors LLC, AIGH Capital Management LLC, Vanguard Group Inc., Samjo Capital LLC, Worth Venture Partners LLC, Morgan Stanley, Morgan Stanley, and PDT Partners LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or or view top insider-buying stocks.

One share of HTGM stock can currently be purchased for approximately $5.99.

HTG Molecular Diagnostics has a market capitalization of $44.39 million and generates $8.55 million in revenue each year. The medical research company earns $-20,870,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis.

HTG Molecular Diagnostics employs 84 workers across the globe.

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

HTG Molecular Diagnostics is headquartered at 3430 E. GLOBAL LOOP, TUCSON AZ, 85706.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at (520) 547-2827.